CELGENE

>

Possible correlations between expression/activity of various proteins/enzymes markers and incidence of myelodysplastic syndrome (MDS) and its development to acute myeloid leukemia (AML) in samples from patients treated and untreated with Lenalidomide, as well as Lenalidomide’s effects on expression/activity of some markers using the leukemic cell lines        

function goBack() { window.history.go(-1); }

Vedúci projektu: Albert Breier (Kontrakt s firmou Celgene)

Trvanie: október 2009 – december 2014
Koordinujúca organizácia: Ústav molekulárnej fyziológie a genetiky SAV

Publikácie:

PubMed Messingerova L, Jonasova A, Barancik M, Polekova L, Seres M, Gibalova L, Breier A, Sulova Z. Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome. Gen Physiol Biophys. 34 (2015) 399–406
Messingerova L, Barancik M, Jonasova A, Seres M, Gibalova L, Breier A, Sulova Z: Effect of lenalidomide therapy on the levels of P-glycoprotein, MRP and matrix matalloproteinases in patients with 5q-myelodysplastic syndrome. In Leukemia Research, 37 (2013) supplement 1, S108-S109.